Parkin - General Information:
Parkin (also known as profenamine hydrochloride) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat parkinsonism. It is sold under the trade names Parsidol in the United States and Parsidan in Canada.
Parkin, a phenothiazine and antidyskinetic, is used in the treatment of Parkinson's disease. By improving muscle control and reducing stiffness, this drug permits more normal movements of the body as the disease symptoms are reduced. It is also used to control severe reactions to certain medicines such as reserpine, phenothiazines, chlorprothixene, thiothixene, loxapine, and haloperidol. Unlike other NMDA antagonists, ethopropazine — because of its anticholinergic action — is largely devoid of neurotoxic side effects. Parkin also has a slight antihistaminic and local anesthetic effect.
Parkin for patients
Several conditions may affect the use of this medicine including a
history of sensitivity to antidyskinetics, breast feeding (as this drug may inhibit lactation), use in children (as
children are more susceptible to anticholinergic effects), and use in the elderly (as the elderly are
predispositioned to glaucoma with chronic use).
When taking this medicine, it is importance not to take more medication than the amount prescribed. If gastric irritation is experienced, taking the drug with food may relieve this condition. If you miss a dose, take it as soon as possible, but not within 2 hours of the next dose. Do not double dose. Regular visits to physician to check progress during prolonged therapy; eye examination may be needed while you are taking this medicine. Avoid alcohol or other CNS depressants. Also, avoiding use of antidiarrheal medications within 1 or 2 hours of taking this medication.
Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects. It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action. Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
Ethopropazine is contraindicated for the treatment of patients with cardiovascular instability, as it may increase the risk of cardiac arrhythmias. Ethopropazine may aggravate tardive dyskinesia, may cause a mydriatic effect resulting in increased intraocular pressure and may precipitate an acute attack of angle-closure glaucoma, and is also contraindicated for patients with hepatic impairment, as the drug's metabolism may be altered. Ethopropazine may also aggravate hypertension, myasthenia gravis, urinary retention, and moderate to severe prostatic hypertrophy.
Other Brand Names containing Ethopropazine:
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..